Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of preventable morbidity and mortality and is increasingly recognized as a chronic vascular disease. Although direct oral anticoagulants (DOACs) have simplified management, clinically important limitations remain. Major bleeding still occurs in roughly 2-4% of treated patients per year and clinically relevant nonmajor bleeding in 10-12%, while post-thrombotic syndrome (PTS) after proximal DVT and persistent functional limitation after PE continue to impair quality of life. This narrative review synthesizes emerging pharmacological strategies beyond conventional anticoagulation, with emphasis on the maturity of evidence and on the distinction between thromboprophylaxis, treatment of acute VTE, secondary prevention, and adjunctive thrombus-resolution approaches. Factor XI/activated factor XI (FXI/FXIa) inhibition is the most mature bleeding-sparing platform. In orthopedic thromboprophylaxis, abelacimab, FXI antisense oligonucleotides, milvexian, and osocimab reduced postoperative venous thrombosis with low bleeding signals, but most data still come from prophylaxis rather than treatment trials. By contrast, fibrinolysis-enhancing strategies targeting α2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1), or thrombin-activatable fibrinolysis inhibitor (TAFI) seek to accelerate endogenous clot resolution and possibly reduce long-term disability, yet current clinical evidence remains early phase. Thrombo-inflammatory approaches targeting selectins or P-selectin glycoprotein ligand-1 (PSGL-1) have strong mechanistic rationale but limited direct clinical confirmation. Overall, the VTE pipeline is moving from broad suppression of coagulation toward mechanism-based strategies matched to specific clinical problems: bleeding-sparing anticoagulation, safer clot-resolution adjuncts, and therapies directed at vein wall injury. At present, FXI inhibition appears closest to clinical translation, whereas fibrinolysis-enhancing and thrombo-inflammatory approaches remain exploratory. Wider adoption will depend on phase 3 treatment outcomes, evidence in cancer and organ dysfunction, reversibility, cost-effectiveness, and integration into clinical guidelines.